AbbVie’s Allergan, Taro Settle Patent Suit on Rosacea Drug

AbbVie’s Allergan and EPI Health had claimed that Taro’s proposed generic version of Rhofade infringes seven patents for the rosacea treatment.

• Each party waived any right to appeal stipulation and order of dismissal approved Monday in federal court in Wilmington, Delaware
  • A trial had been set to begin Nov. 8
• Aclaris Therapeutics and Allergan filed the suit in October 2019; EPI later replaced Aclaris as a plaintiff
  • EPI acquired the rights to Rhofade cream and related intellectual property assets from Aclaris for $55 million in October 2019
• Patents expire in January and August 2024, May 2028 and June ...